Ipsen Stock: Shares Cross 151 Euros, Boosted by Strong Results and Raised Forecasts

Annual Financial Results and Updated Forecasts

The biopharmaceutical group Ipsen published its annual accounts yesterday, reporting a 10.9% growth in revenue for 2025, along with an improvement in operating results. For the 2026 fiscal year, the management now anticipates revenue growth exceeding 13% at constant exchange rates, a target significantly more ambitious than previous indications. This momentum is fueled by the strong performance of the oncology and rare diseases franchises, which are at the core of the company's portfolio. The upward revision of annual targets reflects the management's confidence in the group's commercial trajectory, with the stock now showing a performance increase of over 27% over the past year.

UBS Raises Price Target

This Friday, February 13, UBS raised its price target on Ipsen from 137 to 155 euros, while maintaining a neutral recommendation. With the current price at 151.40 euros, the implied upside potential relative to this new target is approximately 2.4%. This adjustment follows the release of the annual results, which evidently led the Swiss bank to reevaluate its projections. Technically, the stock is trading above its 50-day moving average, which is at 128.16 euros, and has significantly distanced itself from its 200-day moving average (116.06 euros), confirming the bullish trend that has been established in recent weeks. However, the RSI stands at 75, a level indicating that the stock is entering an overbought zone, suggesting that the recent acceleration in price might mechanically slow down or undergo a consolidation phase in the short term. The previous resistance at 147.60 euros, corresponding to the previous day's closing price, was breached this morning.